Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Los Angeles, CA
Treatments:ChemotherapyHospital:Cedars-Sinai Medical Center
Drugs:Journal:Link
Date:Feb 2012

Description:

Patients:
This study involved women with recurrent ovarian cancer who were separated into two separate treatment groups. Group A had 53 patients with a median age of 59 years. Group B had 55 patients with a median age of 62 years.

Treatment:
Patients in group A were treated with the chemotherapy agent paclitaxel and the biologic therapy agent AMG386, which is an inhibitor of proteins involved in getting a blood supply to the tumor.

Patients in group B were treated with paclitaxel only.

Toxicities:
There was one treatment-related death due to an unspecified cause in group A. Grade 3 or higher nerve effects, blood clotting, and bleeding were also reported.

There were 5 treatment-related deaths due to progressive disease and unspecified causes in group B. Blood clots, fatigue, and abdominal pain were also reported.

Results:
The median overall survival rates for groups A and B were 22.5 and 20.9 months, respectively.

Support:
This study was supported by the pharmaceutical company Amgen, makers of AMG 386.

Correspondence: Dr. Beth Y. Karlan; email: [email protected]



Back